Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways.

Obesity is known to be an important risk factor for many types of cancer, such as breast, prostate, liver and endometrial cancer. Recently, epidemiological studies have indicated that obesity correlates with an increased risk of developing ovarian cancer, the most lethal gynecological cancer in developed countries. Leptin is predominantly produced by adipocytes and acts as a growth factor and serum leptin levels positively correlate with the amount of body fat. In this study, we investigated the effects of leptin on the growth of ovarian cancer cells and the underlying mechanism(s) of action. Our results showed that leptin stimulated the growth of the OVCAR-3 ovarian cancer cell line using MTT assay and trypan blue exclusion. Using western blot analysis, we found that leptin enhanced the expression of cyclin D1 and Mcl-1, which are important regulators of cell proliferation and the inhibition of apoptosis. To investigate the signaling pathways that mediate the effects of leptin, cells were treated with leptin plus specific inhibitors of JAK2, PI3K/Akt and MEK/ERK1/2 and analysis of the phosphorylation state of proteins was carried out by western blot assays. We showed that the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways were involved in the growth-stimulating effect of leptin on ovarian cancer cell growth and the specific inhibitors of PI3K/Akt and MEK/ERK1/2 revealed that these two pathways interacted with each other. Our data demonstrate that leptin upregulates the expression of cyclin D1 and Mcl-1 to stimulate cell growth by activating the PI3K/Akt and MEK/ERK1/2 pathways in ovarian cancer.

[1]  Lawrence J Appel,et al.  Prevalence of obesity in the United States. , 2014, JAMA.

[2]  Katherine M Flegal,et al.  Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. , 2012, JAMA.

[3]  L. Poulain,et al.  Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. , 2010, Carcinogenesis.

[4]  S. Dufort,et al.  Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells , 2009, Molecular Cancer Therapeutics.

[5]  K. Al-Kuraya,et al.  Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer , 2009, Molecular Cancer.

[6]  L. Poulain,et al.  Bcl‐XL and MCL‐1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis , 2009, International journal of cancer.

[7]  L. Brinton,et al.  Body mass index and risk of ovarian cancer , 2009, Cancer.

[8]  R. Goldbohm,et al.  Height, Body Mass Index, and Ovarian Cancer: A Pooled Analysis of 12 Cohort Studies , 2008, Cancer Epidemiology Biomarkers & Prevention.

[9]  King-Jen Chang,et al.  Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway. , 2007, Endocrine-related cancer.

[10]  B. Karlan,et al.  Effect of obesity on survival in epithelial ovarian cancer , 2007, Cancer.

[11]  D. Whiteman,et al.  Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. , 2007, European journal of cancer.

[12]  K. Moysich,et al.  Risk of ovarian cancer associated with BMI varies by menopausal status. , 2006, The Journal of nutrition.

[13]  King-Jen Chang,et al.  Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1 , 2006, Breast Cancer Research and Treatment.

[14]  F. Anania,et al.  Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. , 2006, Endocrine-related cancer.

[15]  E. Surmacz,et al.  Leptin and cancer , 2006, Journal of cellular physiology.

[16]  C. Haiman,et al.  Cyclin D1: polymorphism, aberrant splicing and cancer risk , 2006, Oncogene.

[17]  Dan Xu,et al.  Specific Cleavage of Mcl-1 by Caspase-3 in Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis in Jurkat Leukemia T Cells* , 2005, Journal of Biological Chemistry.

[18]  A. Villunger,et al.  The Bcl-2 protein family and its role in the development of neoplastic disease , 2004, Experimental Gerontology.

[19]  D. Mcfadden,et al.  Prostate cancer cell proliferation is influenced by leptin. , 2004, The Journal of surgical research.

[20]  A. Bado,et al.  Leptin Counteracts Sodium Butyrate-induced Apoptosis in Human Colon Cancer HT-29 Cells via NF-κB Signaling* , 2004, Journal of Biological Chemistry.

[21]  Xin Hu,et al.  Leptin--a growth factor in normal and malignant breast cells and for normal mammary gland development. , 2003, Journal of the National Cancer Institute.

[22]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[23]  G. Bray.  The underlying basis for obesity: relationship to cancer. , 2002, The Journal of nutrition.

[24]  O. Katoh,et al.  Increased MCL–1 Expression Is Associated with Poor Prognosis in Ovarian Carcinomas , 2002, Japanese journal of cancer research : Gann.

[25]  T. Key,et al.  Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. , 2002, Journal of the National Cancer Institute.

[26]  M. Thun,et al.  Jewish ethnicity and prostate cancer mortality in two large US cohorts , 2002, Cancer Causes & Control.

[27]  R. Jove,et al.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  M. Kuo,et al.  The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway , 2001, Oncogene.

[29]  Ming-Tsan Lin,et al.  The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6 , 2001, Oncogene.

[30]  Chungming Chang,et al.  Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway , 2000, Oncogene.

[31]  G. Salvesen,et al.  Cleavage of Automodified Poly(ADP-ribose) Polymerase during Apoptosis , 1999, The Journal of Biological Chemistry.

[32]  Min-Liang Kuo,et al.  The Antiapoptotic Gene mcl-1 Is Up-Regulated by the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway through a Transcription Factor Complex Containing CREB , 1999, Molecular and Cellular Biology.

[33]  H. Risch.  Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. , 1999, Journal of the National Cancer Institute.

[34]  Patrick R. Griffin,et al.  Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis , 1995, Nature.

[35]  R. Craig,et al.  Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. , 1994, Cancer research.

[36]  K. Flegal,et al.  Prevalence of obesity in the United States, 2009-2010. , 2012, NCHS data brief.

[37]  P. Leung,et al.  Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. , 2005, The Journal of clinical endocrinology and metabolism.

[38]  井岡 亜希子.  Ovarian cancer incidence and survival by histologic type in Osaka, Japan , 2003 .

[39]  G. Bray,et al.  Drug treatment of obesity. , 2001, Reviews in endocrine & metabolic disorders.